Positive Phase 3 Results for Jazz Pharmaceuticals' Zepzelca and Tecentriq Combo in ES-SCLC Treatment
Jazz Pharmaceuticals plc has announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) for maintenance treatment in adults with extensive-stage small cell lung cancer (ES-SCLC). The trial compared the combination therapy to atezolizumab alone following induction therapy with carboplatin, etoposide, and atezolizumab. The Zepzelca and atezolizumab combination showed a statistically significant improvement. Publish Date: 15-10-2024 Source: Jazz Pharmaceuticals plc Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid and widespread growth, making it one of the most lethal forms of cancer. Unlike limited-stage SCLC (LS-SCLC), which has not yet metastasized and can potentially be cured, ES-SCLC is not curable. ES-SCLC is characterized by widespread lung tumor growth, involvement of the other lung, lymph nodes on the opposite side of the ch...